CDKN2A and neoplasm: While loss of p16INK4a was initially believed to be the main target during cancer progression, the discovery of p14ARF and prevalence of large deletions or silencing of the locus spanning INK4a, ARF and CDKN2B have highlighted the importance of these other tumor suppressors.